Proto-Oncogene Proteins c-kit
"Proto-Oncogene Proteins c-kit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
Descriptor ID |
D019009
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.050 D12.776.543.750.060.124 D12.776.543.750.705.852.150.100 D12.776.543.750.750.400.200.170 D12.776.624.664.700.183 D23.050.301.264.035.590 D23.101.100.110.590
|
Concept/Terms |
Proto-Oncogene Proteins c-kit- Proto-Oncogene Proteins c-kit
- Proto Oncogene Proteins c kit
- c-kit, Proto-Oncogene Proteins
- c-kit Protein
- c kit Protein
- c-kit Receptor
- c kit Receptor
- CD117 Antigen
- CD117 Antigens
- kit Proto-Oncogene Protein
- Proto-Oncogene Protein, kit
- kit Proto Oncogene Protein
- p145 c-kit
- c-kit, p145
- p145 c kit
- p145(c-kit)
- p145c-kit
- p145c kit
- Proto-Oncogene Protein c-kit
- Proto Oncogene Protein c kit
- c-kit, Proto-Oncogene Protein
- Proto-Oncogene Protein kit
- Proto Oncogene Protein kit
- Receptor, Stem Cell Factor
- SCF Receptor
- Stem Cell Factor Receptor
- Antigens, CD117
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-kit".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Proto-Oncogene Proteins c-kit [D08.811.913.696.620.682.725.400.050]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Proto-Oncogene Proteins c-kit [D12.776.543.750.060.124]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Colony-Stimulating Factor [D12.776.543.750.705.852.150]
- Proto-Oncogene Proteins c-kit [D12.776.543.750.705.852.150.100]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Colony-Stimulating Factor [D12.776.543.750.750.400.200]
- Proto-Oncogene Proteins c-kit [D12.776.543.750.750.400.200.170]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Proto-Oncogene Proteins c-kit [D12.776.624.664.700.183]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Proto-Oncogene Proteins c-kit [D23.050.301.264.035.590]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Proto-Oncogene Proteins c-kit [D23.101.100.110.590]
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-kit".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-kit" by people in this website by year, and whether "Proto-Oncogene Proteins c-kit" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 | 2003 | 1 | 0 | 1 | 2004 | 1 | 0 | 1 | 2006 | 1 | 0 | 1 | 2007 | 1 | 0 | 1 | 2010 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2013 | 2 | 0 | 2 | 2014 | 0 | 1 | 1 | 2016 | 0 | 2 | 2 | 2017 | 0 | 1 | 1 | 2018 | 2 | 0 | 2 | 2020 | 1 | 0 | 1 | 2021 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-kit" by people in Profiles.
-
Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 12 01; 27(23):6333-6342.
-
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.
-
Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schöffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2021 04; 26(4):e622-e631.
-
Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.
-
Rangel EB, Gomes SA, Kanashiro-Takeuchi R, Saltzman RG, Wei C, Ruiz P, Reiser J, Hare JM. Kidney-derived c-kit+ progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria. Sci Rep. 2018 10 03; 8(1):14723.
-
Chan IJ, Tharp MD. Comparison of lesional skin c-KIT mutations with clinical phenotype in patients with mastocytosis. Clin Exp Dermatol. 2018 Jun; 43(4):416-422.
-
Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017 Jul 15; 123(14):2688-2697.
-
Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan; 13(1):93-107.
-
Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncol. 2017 Jan; 13(2):185-194.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|